Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization

Journal of Immunology

Volumn 193, Issue 4, 2014, Pages 1828-1835

  White, Ann L ^a   Dou, Lang ^a   Chan, H T Claude ^a   Field, Vikki L ^a   Mockridge, C Ian ^a   Moss, Kane ^a   Williams, Emily L ^a   Booth, Steven G ^a   French, Ruth R ^a   Potter, Elizabeth A ^a   Butts, Cherié ^b   Al Shamkhani, Aymen ^a   Cragg, Mark S ^a   Verbeek, J Sjef ^c   Johnson, Peter W M ^d   Glennie, Martin J ^a   Beers, Stephen A ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b BIOGEN   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 MONOCLONAL ANTIBODY; CHIMERIC PROTEIN; FC RECEPTOR IIB; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2A MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G2AX MONOCLONAL ANTIBODY; MACROGOL; MONOCLONAL ANTIBODY; POLYINOSINIC POLYCYTIDYLIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY MULTIMERIZATION; ARTICLE; B CELL LYMPHOMA; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CROSS LINKING; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STRUCTURE; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN MULTIMERIZATION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; IMMUNOGLOBULIN G; IMMUNOTHERAPY; LYMPHOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; POLY I-C; PROTEIN MULTIMERIZATION; RECEPTORS, IGG; SURFACE PLASMON RESONANCE; TOLL-LIKE RECEPTOR 3;

EID: 84905992571     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1303204     Document Type: Article

References (36)

1. Hodi, F. S. , S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363: 711-723.
2. Beatty, G. L. , E. G. Chiorean, M. P. Fishman, B. Saboury, U. R. Teitelbaum, W. Sun, R. D. Huhn, W. Song, D. Li, L. L. Sharp, et al. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331: 1612-1616.
3. Brahmer, J. R. , S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366: 2455-2465.
4. Topalian, S. L. , F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366: 2443-2454.
5. Wolchok, J. D. , H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, N. H. Segal, C. E. Ariyan, R. A. Gordon, K. Reed, et al. 2013. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369: 122-133.
6. Vonderheide, R. H. , and M. J. Glennie. 2013. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19: 1035-1043.
7. Bulliard, Y. , R. Jolicoeur, M. Windman, S. M. Rue, S. Ettenberg, D. A. Knee, N. S. Wilson, G. Dranoff, and J. L. Brogdon. 2013. Activating Fc g receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 210: 1685-1693.
8. Simpson, T. R. , F. Li, W. Montalvo-Ortiz, M. A. Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J. Y. Henry, H. Yagita, J. D. Wolchok, et al. 2013. Fcdependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210: 1695-1710
9. Selby, M. J. , J. J. Engelhardt, M. Quigley, K. A. Henning, T. Chen, M. Srinivasan, and A. J. Korman. 2013. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1: 32-42.
10. Bennett, S. R. , F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
11. Schoenberger, S. P. , R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
12. French, R. R. , H. T. Chan, A. L. Tutt, and M. J. Glennie. 1999. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5: 548-553.
13. Clynes, R. A. , T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6: 443-446.
14. Uchida, J. , Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199: 1659-1669.
15. Beers, S. A. , R. R. French, H. T. Chan, S. H. Lim, T. C. Jarrett, R. M. Vidal, S. S. Wijayaweera, S. V. Dixon, H. Kim, K. L. Cox, et al. 2010. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115: 5191-5201.
16. Biburger, M. , S. Aschermann, I. Schwab, A. Lux, H. Albert, H. Danzer, M. Woigk, D. Dudziak, and F. Nimmerjahn. 2011. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 35: 932-944.
17. Li, F. , and J. V. Ravetch. 2011. Inhibitory Fcg receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333: 1030-1034.
18. White, A. L. , H. T. Chan, A. Roghanian, R. R. French, C. I. Mockridge, A. L. Tutt, S. V. Dixon, D. Ajona, J. S. Verbeek, A. Al-Shamkhani, et al. 2011. Interaction with FcgRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187: 1754-1763.
19. Slavin, S. , and S. Strober. 1978. Spontaneous murine B-cell leukaemia. Nature 272: 624-626.
20. Illidge, T. , J. Honeychurch, W. Howatt, F. Ross, B. Wilkins, and M. Cragg. 2000. A new in vivo and in vitro B cell lymphoma model, pi-BCL1. Cancer Biother. Radiopharm. 15: 571-580.
21. Hasbold, J. , C. Johnson-Léger, C. J. Atkins, E. A. Clark, and G. G. Klaus. 1994. Properties of mouse CD40: cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies. Eur. J. Immunol. 24: 1835-1842.
22. Glennie, M. J. , H. M. McBride, A. T. Worth, and G. T. Stevenson. 1987. Preparation and performance of bispecific F(ab9 gamma)2 antibody containing thioether-linked Fab9 gamma fragments. J. Immunol. 139: 2367-2375.
23. Williams, E. L. , A. L. Tutt, R. R. French, H. T. Chan, B. Lau, C. A. Penfold, C. I. Mockridge, A. Roghanian, K. L. Cox, J. S. Verbeek, et al. 2012. Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcgRIIB (CD32B). Eur. J. Immunol. 42: 2109-2120.
24. Yu, S. , R. Dunn, M. R. Kehry, and H. Braley-Mullen. 2008. B cell depletion inhibits spontaneous autoimmune thyroiditis in NOD. H-2h4 mice. J. Immunol. 180: 7706-7713.
25. Glennie, M. J. , J. Honeychurch, R. R. French, and A. L. Tutt. 2000. The application of monoclonal antibodies in the treatment of lymphoma. Methods Mol. Med. 40: 85-97.
26. Hamaguchi, Y. , Y. Xiu, K. Komura, F. Nimmerjahn, and T. F. Tedder. 2006. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203: 743-753.
27. White, A. L. , H. T. Chan, R. R. French, S. A. Beers, M. S. Cragg, P. W. Johnson, and M. J. Glennie. 2013. FcgRIIB controls the potency of agonistic anti-TNFR mAbs. Cancer immunology, immunotherapy. CII 62: 941-948.
28. An, H. J. , Y. J. Kim, D. H. Song, B. S. Park, H. M. Kim, J. D. Lee, S. G. Paik, J. O. Lee, and H. Lee. 2011. Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation. J. Biol. Chem. 286: 11226-11235.
29. Haswell, L. E. , M. J. Glennie, and A. Al-Shamkhani. 2001. Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur. J. Immunol. 31: 3094-3100.
30. Elgueta, R. , M. J. Benson, V. C. de Vries, A. Wasiuk, Y. Guo, and R. J. Noelle. 2009. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229: 152-172.
31. Engel, A. L. , G. E. Holt, and H. Lu. 2011. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Exp. Rev. Clin. Pharmacol. 4: 275-289.
32. Flygare, J. A. , T. H. Pillow, and P. Aristoff. 2013. Antibody-drug conjugates for the treatment of cancer. Chem. Biol. Drug Des. 81: 113-121.
33. Li, F. , and J. V. Ravetch. 2013. Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo. Proc. Natl. Acad. Sci. USA 110: 19501-19506.
34. Li, F. , and J. V. Ravetch. 2012. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcg receptor engagement. Proc. Natl. Acad. Sci. USA 109: 10966-10971.
35. Kim, J. M. , and A. Ashkenazi. 2013. Fcg receptors enable anticancer action of proapoptotic and immune-modulatory antibodies. J. Exp. Med. 210: 1647-1651.
36. Smyth, M. J. , and M. H. Kershaw. 2011. Immunology. The adjuvant effects of antibodies. Science 333: 944-945.